Liraglutide Market

Liraglutide Market Analysis

The Liraglutide Market size is estimated at USD 3.51 billion in 2025, and is expected to reach USD 4.10 billion by 2030, at a CAGR of 3.16% during the forecast period (2025-2030).

The COVID-19 pandemic co-morbidities included hypertension, diabetes, cardiovascular disease, and cancer. According to an article,” 89-LB: COVID-19 Outcomes in Patients Who Started GLP1-RAs during Hospitalization,” published by the American Diabetes Association in June 2022, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were considered beneficial in improving COVID-19 outcomes due to their anti-inflammatory properties. Patients admitted for severe interstitial bilateral pneumonia in the COVID-19 ward due to SARS-COV2 infection and having type-2 diabetes or in-hospital hyperglycemia were treated with GLP-1 RAs in addition to standard therapy.

Furthermore, the Centers for Disease Control highlighted that COVID-19 was a serious public health threat for people with serious chronic diseases, including diabetes. People with diabetes were more likely to experience complications when infected with the virus. As per the American Diabetes Association, people with diabetes, if uncontrolled, had worse outcomes if infected with a virus such as COVID-19. The International Diabetes Federation explained that when people with diabetes develop a viral infection, it can be harder to treat due to fluctuations in blood glucose levels and diabetes complications as the immune system is compromised, making it harder to fight the virus and likely leading to a longer recovery period.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type-2 diabetes and chronic obesity. It is used when diet and exercise alone do not result in good blood sugar control. It is a second-line therapy for diabetes, following first-line therapy with metformin. It is also used to help reduce the risk of heart and blood vessel problems, including heart attacks and strokes in patients with type-2 diabetes and established heart or blood vessel disease. Liraglutide is sold under the brand names Victoza and Saxenda.

The World Health Assembly Resolution 2022 recommends the integration of prevention and treatment of diabetes into primary health services, the development of pathways for a substantial increase in access to insulin, the promotion of convergence and harmonization of regulatory requirements for diabetes medicines and technologies, and improved diabetes monitoring and surveillance. Furthermore, it involves the WHO to advise the Member States to ensure the uninterrupted treatment of people living with diabetes in humanitarian emergencies. This important milestone provides a global mandate for diabetes efforts for the next decade.

Major factors that are expected to boost the growth of the studied market in the forecast period are rising obesity and inactivity rates among people, which have resulted in an increase in the diabetes population over time, a rise in the sedentary lifestyle, improper dietary patterns, and the inherent history of diabetes disorders. In addition, rising investment in research and development, technological developments, and new product launches will further provide potential opportunities for the growth of glucagon-like peptide 1 (GLP-1) agonists over the forecast period.

Liraglutide Market Trends

Victoza is expected to register the highest growth rate over the forecast period.

Victoza is expected to register the highest growth rate of over 4.21% over the forecast period.

Victoza is used with a diet and exercise program to control blood sugar levels in adults and children 10 years of age and older with type-2 diabetes when other medications did not control levels well. Victoza is also used to reduce the risk of a heart attack, stroke, or mortality in adults with type-2 diabetes mellitus and heart and blood vessel disease. Victoza is not used to treat type 1 diabetes or diabetic ketoacidosis in adults.

Teva Pharmaceuticals agreed to a patent litigation settlement with Novo Nordisk that would see the generic drugmaker wait until December 2023 to begin marketing its generic version of the type-2 diabetes drug Victoza. Novo Nordisk filed a lawsuit in March 2017 after Teva submitted an ANDA application to the FDA seeking approval for a generic version of the drug. Novo Nordisk alleged that Teva was engaging in patent infringement. The Federal Trade Commission and the Department of Justice awarded Teva a license to launch a generic version of Victoza starting December 22, 2023.

The major factors attributing to the growth of the market studied are an increase in obesity among people and a rising prevalence rate of type-2 diabetes and heart diseases. People with more fat in their bodies are highly likely to be affected by diabetes. According to the United Nations estimates published in March 2022, more than one billion people worldwide were obese, including 650 million adults, 340 million adolescents, and 39 million children, and the numbers are likely to rise. The World Health Organization predicted that by 2025, roughly 167 million people are likely to become overweight or obese. Furthermore, as per World Obesity Atlas 2023, the estimates for global levels of overweight and obesity (BMI ≥25kg/m²) suggest that over 4 billion people may be affected by 2035. The prevalence of obesity (BMI ≥30kg/m²) alone is anticipated to rise to 24% of the population over the same period, affecting nearly 2 billion adults, children, and adolescents by 2035.

Hence, owing to the high burden of obesity, the increasing prevalence of diabetes and expected new product launches are expected to fuel market growth over the forecast period.

North America held the highest market share in the current year

The North American region held the highest market share in the current year.

In the North American region, the prevalence of diabetes has increased dramatically during the last two decades, a fact driven by the increased prevalence of obesity and lifestyle changes owing to less physical activity, unhealthy food habits, and other lifestyle factors. According to the Centers for Disease Control and Prevention (CDC) press release in November 2023, more than one in three Americans are at increased risk for type 2 diabetes. Furthermore, more than 1 in 3 adults, i.e., about 98 million Americans, have prediabetes, and 81% of them are unaware of the condition. Similarly, the Government of Canada in October 2022 estimated that over 3 million Canadians, or 8.9% of the population, have been diagnosed with diabetes. After adjusting for the aging population over time, the prevalence has been increasing at an average rate of 3.3% per year. In addition, 6.1% of Canadian adults have prediabetes, putting them at high risk of developing type-2 diabetes.

The American Diabetes Association (ADA), the Endocrine Society, the American College of Physicians, the American Academy of Paediatrics, the Society of General Internal Medicine, and the National Academy of Medicine published statements and issued calls to action to address social determinants of health at the individual, organizational, and policy levels. ADA also published a scientific review describing the associations between SDOH and diabetes risk and outcomes, focusing on socioeconomic status, health literacy, the food environment, food insecurity, and neighborhood and physical environments, among other topics.

The Centers for Disease Control and Prevention (CDC) National Diabetes Statistics Report 2022 estimated that more than 130 million adults are living with diabetes or prediabetes in the United States. Type-2 diabetes is more common, and diabetes is more consequential among communities of color, those who live in rural areas, and those with less education, lower incomes, and lower health literacy.

Therefore, the studied market is anticipated to grow over the analysis period due to rising prevalence and the factors above.

Liraglutide Industry Overview

The Liraglutide Market is consolidated with no generic products.

Liraglutide Market Leaders

Liraglutide Market News

• October 2023: Global biopharmaceutical company Biocon announced a partnership with Juno Pharmaceuticals, a specialty pharmaceutical firm based in Canada, for the commercialization of Liraglutide, a drug-device combination intended for the treatment and management of type-2 diabetes and obesity in the Canadian market. Under the agreement's terms, Biocon will be responsible for obtaining regulatory approvals for Liraglutide and will subsequently manage the manufacturing and distribution of the product within Canada.
• March 2023: In response to a global supply issue for dulaglutide (brand name Trulicity), a treatment for type-2 diabetes, Pharmac (New Zealand) decided to fund Liraglutide (brand name Victoza) as an alternative treatment. As a part of a supply agreement with Novo Nordisk New Zealand Limited, Liraglutide will be funded for people with type-2 diabetes who meet the current eligibility criteria for GLP-1 agonists.